[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"f4599b74-514d-415f-a4c1-0ad32a88ef07","acronym":"A071401","url":"https://clinicaltrials.gov/study/NCT02523014","created_at":"2021-01-18T12:11:52.655Z","updated_at":"2025-02-25T13:11:46.229Z","phase":"Phase 2","brief_title":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas","source_id_and_acronym":"NCT02523014 - A071401","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation","tags":["PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 09/28/2015","start_date":" 09/28/2015","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-01-15"},{"id":"613dfa54-e318-471f-a8ed-a12b2572968b","acronym":"CAPTUR","url":"https://clinicaltrials.gov/study/NCT03297606","created_at":"2021-01-18T16:17:30.914Z","updated_at":"2025-02-25T13:52:23.697Z","phase":"Phase 2","brief_title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","source_id_and_acronym":"NCT03297606 - CAPTUR","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • sunitinib • Perjeta (pertuzumab) • Cotellic (cobimetinib) • bosutinib • Tukysa (tucatinib) • temsirolimus • axitinib • Erivedge (vismodegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-11-12"},{"id":"03fa7b60-29a0-4a44-aa05-14a8b5df45eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02091141","created_at":"2021-01-17T17:15:36.027Z","updated_at":"2025-02-25T12:26:06.921Z","phase":"Phase 2","brief_title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02091141","lead_sponsor":"Genentech, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation","tags":["EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • erlotinib • Zelboraf (vemurafenib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 673","initiation":"Initiation: 04/14/2014","start_date":" 04/14/2014","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2024-07-23"},{"id":"b2ee5075-c228-40d0-b9ee-e5526535926f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00878163","created_at":"2021-01-18T03:21:25.984Z","updated_at":"2024-07-02T16:35:15.360Z","phase":"Phase 1","brief_title":"GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT00878163","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gemcitabine • Erivedge (vismodegib) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 03/31/2009","start_date":" 03/31/2009","primary_txt":" Primary completion: 01/22/2013","primary_completion_date":" 01/22/2013","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-03-11"},{"id":"1d2920ad-7680-4e69-b51f-ddb29e043f61","acronym":"ACT","url":"https://clinicaltrials.gov/study/NCT05238831","created_at":"2023-08-08T16:08:43.868Z","updated_at":"2025-02-25T12:28:40.109Z","phase":"Phase 1","brief_title":"SMMART Adaptive Clinical Treatment (ACT) Trial","source_id_and_acronym":"NCT05238831 - ACT","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" HR positive • HER-2 negative • EGFR positive","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • carboplatin • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • capecitabine • Piqray (alpelisib) • Zejula (niraparib) • albumin-bound paclitaxel • fulvestrant • irinotecan • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • Herzuma (trastuzumab-pkrb) • anastrozole • Erivedge (vismodegib) • Trazimera (trastuzumab-qyyp) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • EG1206A (pertuzumab biosimilar)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/30/2023","start_date":" 01/30/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-01-23"},{"id":"ec42b0ca-8ef6-412c-ad74-499ce7f4d1b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05538091","created_at":"2022-09-13T11:56:07.406Z","updated_at":"2024-07-02T16:35:27.786Z","phase":"Phase 2","brief_title":"Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer","source_id_and_acronym":"NCT05538091","lead_sponsor":"Ronald Buckanovich","biomarkers":" BRCA • CD4","pipe":"","alterations":" ","tags":["BRCA • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Erivedge (vismodegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 05/15/2023","start_date":" 05/15/2023","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-11-29"},{"id":"a8b6f6a9-6202-45d1-8f50-d1a889349779","acronym":"NOA-20","url":"https://clinicaltrials.gov/study/NCT03158389","created_at":"2021-01-18T15:34:18.016Z","updated_at":"2024-07-02T16:35:35.452Z","phase":"Phase 1/2","brief_title":"NCT Neuro Master Match - N²M² (NOA-20)","source_id_and_acronym":"NCT03158389 - NOA-20","lead_sponsor":"University Hospital Heidelberg","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Ibrance (palbociclib) • Alecensa (alectinib) • temsirolimus • Erivedge (vismodegib) • idasanutlin (RG7388) • Apocept (asunercept)"],"overall_status":"Completed","enrollment":" Enrollment 228","initiation":"Initiation: 05/07/2018","start_date":" 05/07/2018","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 02/22/2023","study_completion_date":" 02/22/2023","last_update_posted":"2023-09-28"},{"id":"79383924-a193-49a9-829a-e82787434ada","acronym":"","url":"https://clinicaltrials.gov/study/NCT02115828","created_at":"2021-01-18T09:47:28.933Z","updated_at":"2024-07-02T16:37:08.789Z","phase":"Phase 1","brief_title":"A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy","source_id_and_acronym":"NCT02115828","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" AKT1 • GLI1","pipe":" | ","alterations":" GLI1 expression","tags":["AKT1 • GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2018-07-20"},{"id":"801546e5-690b-45d4-91eb-788913d198fc","acronym":"SHH-CM","url":"https://clinicaltrials.gov/study/NCT02694224","created_at":"2021-01-18T13:09:09.118Z","updated_at":"2025-02-25T16:30:46.376Z","phase":"Phase 2","brief_title":"Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT02694224 - SHH-CM","lead_sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • cyclophosphamide • epirubicin • Erivedge (vismodegib)"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2017-10-24"},{"id":"00c91ab4-92f1-495c-8d93-32c76994ed4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00980343","created_at":"2021-01-18T03:49:30.966Z","updated_at":"2024-07-02T16:37:18.798Z","phase":"Phase 2","brief_title":"GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery","source_id_and_acronym":"NCT00980343","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ","pipe":"","alterations":" ","tags":["Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 06/01/2012","study_completion_date":" 06/01/2012","last_update_posted":"2017-08-16"},{"id":"ef8dc717-a1f6-482f-b962-296b47ecd4a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01195415","created_at":"2021-01-18T04:47:05.372Z","updated_at":"2024-07-02T16:37:19.135Z","phase":"Phase 2","brief_title":"Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer","source_id_and_acronym":"NCT01195415","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD24","pipe":"","alterations":" ","tags":["CD24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 10/10/2014","study_completion_date":" 10/10/2014","last_update_posted":"2017-08-07"},{"id":"91c39a53-7b26-43ba-800c-a0860fbba5a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00739661","created_at":"2021-01-18T02:47:28.448Z","updated_at":"2024-07-02T16:37:21.282Z","phase":"Phase 2","brief_title":"A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission","source_id_and_acronym":"NCT00739661","lead_sponsor":"Genentech, Inc.","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 104","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 11/01/2010","study_completion_date":" 11/01/2010","last_update_posted":"2017-06-08"}]